

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 60052

**Title:** Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: a case report

**Reviewer's code:** 00183481

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Assistant Professor

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** Italy

**Manuscript submission date:** 2020-10-13

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-10-14 06:22

**Reviewer performed review:** 2020-10-15 12:28

**Review time:** 1 Day and 6 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## **SPECIFIC COMMENTS TO AUTHORS**

Authors reported a very rare case with mucinous cystadenocarcinoma (MCAC) of the pancreas treated with olaparib. The patient has a very long medical history because she primarily consulted the center in 2008 and has been treated until now. She was successfully treated with two surgical resections and chemotherapy with GEMOX. Eventually in 2019 she had the recurred lesion again and treated with FOLFIRINOX. Genetic examination showed a BRCA1 variant and maintenance olaparib treatment was conducted. This is the first case report of MCAC treated with olaparib. The clinical course is quite impressive, and the effectiveness of the PARP inhibitor against BRCA1 mutated pancreatic carcinoma should be emphasized. Although, there are still some queries. Major points 1. A rare case with pancreatic mucinous cystadenocarcinoma is presented, The histological examination of surgically resected tissue should be shown. Immunohistochemical analysis with mucin specific staining would be informative. 2. Mucinous cyst adenocarcinoma of the pancreas is a rare malignancy and a low grade tumor compared with ductal adenocarcinoma. POLO trial reported in NEJM showed DFS rate at 6 months in olaparib group is 53%. This case was treated for 3 months and effectiveness was checked with PET-CT. More longer follow-up would be impressive. The patient should be treated for more than 6 months now. Please update the follow-up result. 3. The method for BRCA analysis is not written. The assessment of this BRCA1 c.41117G>T variant should be conducted. When it is a pathogenic variant, the checked database should be indicated. 4. In discussion, “screening for BRCA mutations was offered only to those patient with a family history” does not have references. This historical indication is limited in Italy? As authors mentioned, NCCN guidelines recommended BRCA germline testing for pancreatic cancers. A mucinous cystadenocarcinoma should be included. Minor points 1. A CARE checklist needs



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

lines/pages. 2. In Figure 1, what is the difference between A and B? 3. The value of CEA levels should be shown after chemotherapy with FOLFIRINOX and olaparib. 4. 18F-FDG PET-CT is accurate.

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 60052

**Title:** Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRC germline mutation effectively treated with olaparib: a case report

**Reviewer's code:** 00183481

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Assistant Professor

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** Italy

**Manuscript submission date:** 2020-10-13

**Reviewer chosen by:** Han Zhang (Part-Time Editor)

**Reviewer accepted review:** 2020-11-02 10:38

**Reviewer performed review:** 2020-11-02 10:52

**Review time:** 1 Hour

<b>Scientific quality</b>	[ <input checked="" type="checkbox"/> ] Grade A: Excellent [ <input type="checkbox"/> ] Grade B: Very good [ <input type="checkbox"/> ] Grade C: Good [ <input type="checkbox"/> ] Grade D: Fair [ <input type="checkbox"/> ] Grade E: Do not publish
<b>Language quality</b>	[ <input checked="" type="checkbox"/> ] Grade A: Priority publishing [ <input type="checkbox"/> ] Grade B: Minor language polishing [ <input type="checkbox"/> ] Grade C: A great deal of language polishing [ <input type="checkbox"/> ] Grade D: Rejection
<b>Conclusion</b>	[ <input checked="" type="checkbox"/> ] Accept (High priority) [ <input type="checkbox"/> ] Accept (General priority) [ <input type="checkbox"/> ] Minor revision [ <input type="checkbox"/> ] Major revision [ <input type="checkbox"/> ] Rejection
<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No

## SPECIFIC COMMENTS TO AUTHORS



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

The authors revised the manuscript appropriately. This paper is well written and extremely interesting.